Incomplete remission and treatment resistance in first-episode psychosis: Definition, prevalence and predictors

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 12, 2008, Pages 2027-2038

  Hubert, Christian G ^a   Naber, Dieter ^a   Lambert, Martin ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Definition; Incomplete remission; Predictors; Psychosis; Treatment resistance

Indexed keywords

CARBAMAZEPINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; NEUROLEPTIC AGENT; TRANQUILIZER; VALPROIC ACID;

ADAPTATION SYNDROME; BIPOLAR DISORDER; DISEASE DURATION; DISEASE SEVERITY; EARLY DIAGNOSIS; FIRST EPISODE PSYCHOSIS; FUNCTIONAL STATUS; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PREDICTION; PREVALENCE; PSYCHOLOGICAL ASPECT; PSYCHOSIS; QUALITY OF LIFE; REMISSION; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; THERAPY DELAY; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE;

DRUG RESISTANCE; HUMANS; PREVALENCE; PROGNOSIS; PSYCHOTIC DISORDERS; RECURRENCE; REMISSION INDUCTION; TREATMENT FAILURE;

EID: 50949122430     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.12.2027     Document Type: Review

References (125)

1. Conus P, Cotton S, Schimmelmann BG, et al. The First-episode Psychosis Outcome Study: premorbid and baseline characteristics of an epidemiological cohort of 661 first-episode psychosis patients. Early Intervent Psychiatry 2007;1:191-200
2. Schimmelmann BG, Conus P, Edwards J, et al. Diagnostic stability 18 months after treatment initiation for first-episode psychosis. J Clin Psychiatry 2005;66(10):1239-46
3. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia proposed criteria and rationale for consensus. Am J Psychiatry 2005;162(3):441-9
4. Lambert M, Naber D, Huber CG. Management of incomplete remission and treatment resistance in first-episode psychosis. Expert Opin Pharmacother 2008;9(12):2039-51
5. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45(9):789-96
6. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156(4):544-9
7. Lambert M, Naber D. Current issues in schizophrenia: ovcrview of patient acceptability, functioning capacity and quality of life. CNS Drugs 2004;18 (Suppl 2):5-17; discussion 41-3
8. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996;153(7):948-50
9. Craig T, Fennig S, Tanenberg-Karant M, Bromet EJ. Six-month clinical status as a predictor of 24-month clinical outcome in first-admission patients with schizophrenia. Ann Clin Psychiatry 1999;11(4):197-203
10. Lambert M, Conus P, Klosterkötter J, et al. Results of First-Episode Psychosis Outcome Study (FEPOS) and resulting treatment recommendations. Nervenarzt In press
11. Marneros A. Schizoafftctive disorder: clinical aspects, differential diagnosis, and treatment. Curr Psychiatry Rep 2003;5(3):202-5
12. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenin In: American Psychiatric Association, editors, Practice guidelines for the treatment of psychiatric disorders, Compendium 2004. 2nd edition. Arlington, VA: American Psychiatric Publishing; 2004. p. 249-440
13. Peuskens J. The evolving definition of treatment resistance. J Clin Psychiatry 1999;60(Suppl 12):4-8
14. Pantelis C, Lambert TJ. Managing patients with 'treatment-resistant' schizophrenia. Med J Aust 2003;178(Suppl):S62-6
15. Sachs GS. Treatment-resistant bipolar depression. Psychiatr Clin N Am 1996;19(2):215-36
16. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 16):10-7
17. Goldberg JF, Garno JI, Harrow M. Long-term remission and recovery in bipolar disorder: a review. Curr Psychiatry Rep 2005;7(6):456-61
18. Gitlin MJ. Treatment-resistant bipolar disorder. Bull Menninger Clin 2001;65(1):26-40
19. Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006;11(3):227-40
20. Gilmer WS, Trivedi MH, Rush AJ, et al. Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project. Acta Psychiatr Scand 2005;112(6):425-33
21. Malhi GS, Parker GB, Crawford J, et al. Treatment-resistant depression: resistant to definition? Acta Psychiatr Scand 2005;112(4):302-9
22. World Psychiatric Association: Symposium on therapy-resistant depression. Pharmacopsychiatry (1974) 7:69-224.
23. Souery D, Amsterdam J, De Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999;9(1/2):83-91
24. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53(8):649-59
25. Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007;52(1):46-54
26. Buckley PF, Wiggins LD, Sebastian S, Singer B. Treatment-refractory schizophrenia. Curr Psychiatry Rep 2001;3(5):393-400
27. Ram R, Bromet EJ, Eaton WW, et al. The natural course of schizophrepnia: a review of first-admission studies. Schizophr Bull 1992;18(2):185-207
28. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994;151(10):1409-16
29. Lambert M, Conus P, Schimmelmann BG, et al. Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study. Pharmacopsychiatry 2005;38(5):206-13
30. Locbel AD, Lieberman JA, Alvir JM, et al. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992;149(9):1183-8
31. Lieberman J, Jody D, Geisler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993;50(5):369-76
32. Edwards J, Maude D, McGorry PD, et al. Prolonged recovery in first-episodepsychosis. Br J Psychiatry Suppl 1998;172(33):107-16
33. Manchanda R, Norman RM, Malla AK, et al. Persistent psychoses in first episode patients. Schizophr Res 2005;80(1):113-6
34. Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull 1998;24(1):75-85
35. Harrison G, Hopper K, Craig T, et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 2001;178:506-17
36. Robinson DG, Woerner MG, McMeniman M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161(3):473-9
37. Leff J, Sartorius N, Jablensky A, et al. The International Pilot Study of Schizophrenia: five-year follow-up findings. Psychol Mcd 1992;22(1):131-45
38. Lauronen E, Koskinen J, Veijola J, et al. Recovery from schizophrenic psychoses within the northern Finland 1966 Birth Cohort. J Clin Psychiatry 2005;66(3):375-83
39. Torgalsboen AK, Rund BR. 'Full recovery' from schizophrenia in the long term: a ten-year follow-up of eight former schizophrenic patients. Psychiatry 1998;61(1):20-34
40. Tsuang D, Coryell W. An 8-year follow-up of patients with DSM-III-R psychotic depression, schizoaffective disorder, and schizophrenia. Am J Psychiatry 1993;150(8):1182-8
41. Tohen M, Zarate CA Jr, Hennen J, et al. The McLcan-Harvard First-episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry 2003;160(12):2099-107
42. Altshuler LL, Gitlin MJ, Mintz J, et al. Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J Clin Psychiatry 2002;63(9):807-11
43. Strakowski SM, Delbello MP, Fleck DE, et al. Effects of co-occurring alcohol abuse on the course of bipolar disorder following a first hospitalization for mania. Arch Gen Psychiatry 2005;62(8):851-8
44. Judd LL, Akiskal HS, Schetter PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59(6):530-7
45. Kocsis JH. New strategies for treating chronic depression. J Clin Psychiatry 2000;61(Suppl 11):42-5
46. Kennedy SH, Lam RX, Cohen NL, Ravindran AV. Clinical guidelines for die treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001;46(Suppl 1:38S-58S
47. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 2002;63(11):963-71
48. Maki P, Veijola J, Jones PB, et al. Predictors of schizophrenia - a review. Br Med Bull 2005;73/74:1-15
49. Nasrallah HA. Neurologic comorbidities in schizophrenia. J Clin Psychiatry 2005;66(Suppl 6):34-46
50. Lieberman J, Chakos M, Wu H, et al. Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry 2001;49(6):487-99
51. Milev P, Ho BC, Arndt S, et al. Initial magnetic resonance imaging volumetric brain measurements and outcome in schizophrenia: a prospective longitudinal study with 5-year follow-up. Biol Psychiatry 2003;54(6):608-15
52. Mitelman SA, Shihabuddin L, Brickman AM, et al. Volume of the cingulate and outcome in schizophrenia. Schizophr Res 2005;72(2/3):91-108
53. Staal WG, Hulshoff Pol HE, Schnack HG, et al. Structural brain abnormalities in chronic schizophrenia at the extremes of the outcome spectrum. Am J Psychiatry 2001;158(7):1140-2
54. Ho BC, Andreasen NC, Nopoulos P, et al. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry 2003;60(6):585-94
55. Tandon R, Dequardo JR, Taylor SF, et al. Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr Res 2000;45(3):191-201
56. Rocca P, Bellino S, Calvarese P, et al. Depressive and negative symptoms in schizophrenia: different effects on clinical features. Compr Psychiatry 2005;46(4):304-10
57. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005;162(3):495-506
58. Sharma T, Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treament. Psychiatr Clin N Am 2003;26(1):25-40
59. McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr Res 2000;45(3):175-84
60. Lysaker PH, Bryson GJ, Bell MD. Insight and work performance in schizophrenia. J Nerv Ment Dis 2002;190(3):142-6
61. Maggini C, Raballo A. Exploring depression in schizophrenia. Eur Psychiatry 2006;21(4):227-32
62. Semiz UB, Cetin M, Basoglu C, et al. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(6):1330-6
63. Perkins D, Lieberman J, Gu H, et al. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 2004;185:18-24
64. Strous RD, Alvir JM, Robinson D, et al. Premorbid functioning in schizophrenia: relation to baseline symptoms, treatment response, and medication side effects. Schizophr Bull 2004;30(2):265-78
65. Larsen TK, Friis S, Haahr U, et al. Premorbid adjustment in first-episode non-affective psychosis: distinct patterns of pre-onset course. Br J Psychiatry 2004;185:108-15
66. Browne S, Clarke M, Gervin M, et al. Determinants of quality of life at first presentation with schizophrenia. Br J Psychiatry 2000;176:173-6
67. Malla AK, Norman RM, Manchanda R, et al. One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophr Res 2002;54(3):231-42
68. Lambert M, Conus P, Lubman DI, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005;112(2):141-8
69. Green AI, Canuso CM, Brenner MJ, Wojcik JD. Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin N Am 2003;26(1):115-39
70. Ongur D, Goff DC. Obsessive-compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status. Schizophr Res 2005;75(2/3):349-62
71. Braga RJ, Petrides G, Figueira I. Anxiety disorders in schizophrenia. Compr Psychiatry 2004;45(6):460-8
72. Kennedy JS, Jeste D, Kaiser CJ, et al. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. Int J Geriatr Psychiatry 2003;18(11):1013-20
73. Kumra S, Shaw M, Merka P, et al. Childhood-onset schizophrenia: research update. Can J Psychiatry 2001;46(10):923-30
74. Meltzer HY, Rabinowitz J, Lee MA, et al. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry 1997;154(4):475-82
75. Hollis C. Adult outcomes of child- and adolescent-onset schizophrenia: diagnostic stability and predictive validity. Am J Psychiatry 2000;157(10):1652-9
76. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23(4):637-51
77. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63(10):892-909
78. Lindenmayer JP. Treatment refractory schizophrenia. Psychiatr Q 2000;71(4):373-84
79. Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996;57(Suppl 9):5-9
80. Mintz AR, Dobson KS, Romney DM. Insight in schizophrenia: a mem-analysis. Schizophr Res 2003;61(1):75-88
81. McKenzie K, Van Os J, Fahy T, et al. Psychosis with good prognosis in Afro-Caribbean people now living in the United Kingdom. BMJ 1995;311(7016):1325-8
82. Murray RM, Van Os J. Predictors of outcome in schizophrenia. J Clin Psychopharmacol 1998;18(2 Suppl 1):2S-4S
83. Kavanagh DJ: Recent developments in expressed emotion and schizophrenia. Br J Psychiatry 1992;160:601-20
84. Sandson NB, Armstrong SC, Cozza KL. An overview of psychotropic drug-drug interactions. Psychosomatics 2005;46(5):464-94
85. Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004;161(5):780-96
86. Pantetis C, Velakoulis D, McGorry PD, et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003;361(9354):281-8
87. Schimmelmann BG, Huber CG, Lambert M, et al. Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Research 2008; doi: 10.1016/j.jpsychires.2007.12.001
88. Ucok A, Polat A, Genc A, et al. Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia. J Psychiatr Res 2004;38(2):163-8
89. Harrigan SM, McGorry PD, Krstev H. Does treatment delay in first-episode psychosis really matter? Psychol Mcd 2003;33(1):97-110
90. Marshall M, Lewis S, Lockwood A, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005;62(9):975-83
91. Bottlender R, Sato T, Jager M, et al. The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia. Schizophr Res 2003;62(1/2):37-44
92. Harris MG, Henry LP, Harrigan SM, et al. The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. Schizophr Res 2005;79(1):85-93
93. Royal Australian And New Zealand College Of Psychiatrists. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust NZ J Psychiatry 2005;39(1/2):1-30
94. Lambert M, Naber D, editors. Current schizophrenia. Hamburg. Science Press, 2004
95. Moore PB, Shepherd DJ, Eccleston D. et al. Cerebral white matter lesions in bipolar affective disorder: relationship to outcome. Br J Psychiatry 2001;178:172-6
96. Doris A, Belton E, Ebmeier KP, et al. Reduction of cingulate gray matter density in poor outcome bipolar illness. Psychiatry Res. 2004;130(2):153-9
97. Strakowski SM, Delbello MP, Zimmerman ME, et al. Ventricular and periventricular structural volumes in first-versus multiple-episode bipolar disorder. Am J Psychiatry 2002;159(11):1841-7
98. Bearden CE, Hoffman KM, Cannon TD. The neuropsychology and neuroanatomy of bipolar affective disorder: a critical review. Bipolar Dis 2001;3(3):106-50; discussion 103-51
99. Baethge C, Smolka MN, Gruschka P, et al. Does prophylaxis-delay in bipolar disorder influence outcome? Results from a long-term study of 147 patients. Acta Psychiatr Scand 2003;107(4):260-7
100. Bowden CL. Relationship of acute mania symptomatology to maintenance treatment response. Curr Psychiatry Rep 2004;6(6):473-77
101. Nolen WA, Luckenbaugh DA, Altshuler LL, et al. Correlates of 1-year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network. Am J Psychiatry 2004;161(8):1447-54
102. Bauer MS, Kirk GF, Gavin C, Williford WO. Determinants of functional outcome and healthcare costs in bipolar disorder: a high-intensity follow-up study. J Affect Dis 2001;65(3):231-41
103. Martinez-Aran A, Vieta E, Colom F, et al. Neuropsychological performance in depressed and euthymic bipolar patients. Neuropsychobiology 2002;46(Suppl 1):16-21
104. Coryell W, Turvey C, Endicott J, et al. Bipolar I affective disorder: predictors of outcome after 15 years. J Affect Dis 1998;50(2/3):109-16
105. Tsai SM, Chen C, Kuo C, et al. 15-year outcome of treated bipolar disorder. J Affect Dis 2001;63(1/3):215-20
106. Boylan KR, Bieling PJ, Marriott M, et al. Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. J Clin Psychiatry 2004;65(8):1106-13
107. Gaudiano BA, Miller IW. Anxiety disorder comorbidity in bipolar I disorder: relationship to depression severity and treatment outcome. Depress Anxiety 2005;21(2):71-7
108. Carter TD, Mundo E, Parikh SV, Kennedy JL. Early age at onset as a risk factor for poor outcome of bipolar disorder. J Psychiatr Res 2003;37(4):297-303
109. Chengappa KN, Baker RW, Shao L, et al. Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania. Bipolar Dis 2003;5(1):1-5
110. Hirschfeld RM, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. J Clin Psychiatry 2003;64(1):53-9
111. Keck PE Jr, McElroy SL, Strakowski SM, et al. 12-month outcome of patients with bipolar disorder following hospitalization for a martic or mixed episode. Am J Psychiatry 1998;155(5):646-52
112. Baldessarini RJ, Tondo, L, Hennen J. Treatment-latency and previous episodes: relationships to pretreatment morbidity and response to maintenance treatment in bipolar I and Ii disorders. Bipolar Dis 2003;5(3):169-79
113. Craig TJ, Grossman S, Mojtabai R, et al. Medication use Patterns and 2-year outcome in first-admission bipolar disorder with psychotic features. Bipolar Dis 2004;6(5):406-15
114. Perlis RH, Miyahara S, Marangell LB, et al. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2004;55(9):875-81
115. Howland RH. Thyroid dysfunction in refractory depression: implications for pathophysiology and treatment. J Clin Psychiatry 1993;54(2):47-54
116. Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 16):18-25
117. Thase ME. Treatment of severe depression. J Clin Psychiatry 2000;61(Suppl 1):17-25
118. Scott J, Williams JM, Brittlebank A, Ferrier IN. The relationship between premorbid neuroticism, cognitive dysfunction and persistence of depression: a 1-year follow-up. J Affect Dis 1995;33(3):167-72
119. Klein DN, Schatzberg AF, McCullough JP, et al. Age of onset in chronic major depression: relation to demographic and clinical variables, family history, and treatment response. J Affect Dis 1999;55(2/3):149-57
120. Scott J, Barker WA, Eccleston D. The Newcastle Chronic Depression Study. Patient characteristics and factors associated with chronicity. Br J Psychiatry 1988;152:28-33
121. Wetter TC, Ising M. Association between polymorphism within the promoter region of the serotonin transporter gene and treatment response in depression - further evidence but still controversial issues. Sleep Med 2004;5(1):93-5
122. Hirschfeld RM. Clinical importance of long-term antidepressant treatment. Br J Psychiatry Suppl 2001;42:S4-8
123. Melle I, Larsen TK, Haahr U, et al. Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. Arch Gen Psychiatry 2004;61(2):143-50
124. Wunderink A, Nienhuis FJ, Sytema S, Wiersma D. Treatment delay and response rare in first episode psychosis. Acta Psychiatr Scand 2006;113(4):332-9
125. Drake RE, Mueser KT, Torrey WC, et al. Evidence-based treatment of schizophrenia. Curr Psychiatry Rep 2000;2(5):393-7